About InVivoSIM anti-human IgE (Omalizumab Biosimilar) This non-therapeutic biosimilar antibody uses the same variable regions from the therapeutic antibody Omalizumab making it ideal for research use. This Omalizumab biosimilar reacts with free human IgE in blood and interstitial fluid and to membrane-bound IgE on the surface of IgE-expressing B cells. It does not bind to IgE that is already bound by the high affinity IgE receptor (FcεRI) on the surface of mast cells, basophils, and antigen-presenting dendritic cells. It does not provoke histamine release from mast-cells sensitised by IgE. Omalizumab binds an epitope in proximity to the binding site of the FcεRI. InVivoSIM anti-human IgE (Omalizumab Biosimilar) Specifications IsotypeHuman IgG1, κ Recommended Isotype Control(s)RecombiMAb human IgG1 isotype control, anti-hen egg lysozyme Recommended Dilution BufferInVivoPure pH 7.0 Dilution Buffer ImmunogenHuman IgE Reported ApplicationsIgE neutralizationFlow cytometryELISA FormulationPBS, pH 7.0 Contains no stabilizers or preservatives Endotoxin<0.5EU/mg (<0.0005EU/μg) Determined by LAL gel clotting assay Aggregation<5% Determined by SEC Purity>95% Determined by SDS-PAGE Sterility0.2 μm filtration PurificationProtein A RRIDAB_2927532 Molecular Weight150 kDa StorageThe antibody solution should be stored at the stock concentration at 4°C. Do not freeze.
